VJOncology is committed to improving our service to you

BOPA/ISOPP 2019 | Potential role of rituximab in mCRPC

VJOncology is committed to improving our service to you

Lisa Holle

Lisa Holle, PharmD, BCOP, FHOPA, University of Connecticut School of Pharmacy, Storrs, CT, reviews a recent case study of a patient with castrate-resistant prostate cancer who responded to treatment for a secondary folliular lymphoma following treatment with rituximab. This interview took place at the International Society of Oncology Pharmacy Practitioners (ISOPP) Symposium 2019, hosted by the British Oncology Pharmacy Association (BOPA), held in London, UK.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter